MAP2K7 and melanoma: Pyrexia occurred in 14.6% of patients, a lower rate than observed with other BRAF / MEK inhibitor combinations such as dabrafenib and trametinib.5 Thus, the combination of encorafenib and binimetinib demonstrated a manageable safety profile in patients with melanoma BM.